RxDoctor Payments DataLook up a doctor →

Ronald Dagostino, DO

Cardiovascular Disease · Lake Success, NYNPI 1831134865

Payments from drug & device makers

$813,903in general payments, 2019–2025

Across 2,102 payments — averaging $387.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$194K
  • Lilly USA, LLC$185K
  • Johnson & Johnson$81K
  • Amgen$77K
  • Boston Scientific$69K
  • Novo Nordisk$50K
  • plus $157K from 47 others

What the payments were for

  • Consulting fees$61,4438%
  • Speaking & faculty fees$627,06380%
  • Travel & lodging$42,9865%
  • Food & beverage$50,6756%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$813,903 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$692,061
Medicare patients
468
Services billed
4,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin678$835,706
XareltoRivaroxaban440$493,895
MounjaroTirzepatide185$230,440
OzempicSemaglutide124$198,340
VascepaIcosapent Ethyl217$142,615
TrulicityDulaglutide80$123,551
EntrestoSacubitril/Valsartan72$95,765
Repatha SureclickEvolocumab97$91,463
EliquisApixaban60$77,528
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$67,476
Icosapent Ethyl159$56,933
JanuviaSitagliptin Phosphate38$33,344
VerquvoVericiguat35$32,317
Eplerenone449$29,591
Rosuvastatin Calcium1,576$25,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$194,480$835,706678 claims
Johnson & JohnsonXarelto$81,177$493,895440 claims
Lilly USA, LLCMounjaro, Trulicity$184,912$353,991265 claims
Novo NordiskOzempic, Wegovy$50,364$217,983138 claims
NovartisEntresto$1,995$95,76572 claims
PfizerEliquis$1,023$77,52860 claims
AstraZenecaBreztri Aerosphere$13,741$67,47669 claims
MerckJanuvia, Verquvo$1,865$65,66173 claims
Esperion Therapeutics, Inc.Nexlizet$363$15,13232 claims
AbbVieSynthroid$335$5,75885 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Lake Success

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →